RegCell develops cell therapies designed to restore immune tolerance in autoimmune diseases.
RegCell has raised $44.0M in total funding. The most recent round was Series A. The last funding was announced in September 2026.
RegCell's investors include Alumni Ventures, Mitsubishi UFJ Capital, Playground Global, Global Brain Corporation, UTEC - The University of Tokyo Edge Capital Partners.
RegCell is headquartered in Emeryville, United States.
RegCell develops cell therapies designed to restore immune tolerance in autoimmune diseases.
RegCell is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"RegCell — Funding & Investors." VCBacked, September 15, 2026, https://www.vcbacked.co/company/regcell. Accessed November 12, 2026.
VCBacked. (2026). RegCell — Funding & Investors. Retrieved November 12, 2026, from https://www.vcbacked.co/company/regcell
{{cite web |title=RegCell — Funding & Investors |url=https://www.vcbacked.co/company/regcell |website=VCBacked |access-date=November 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at RegCell? Request a listing update